In the phase III VERONA trial, venetoclax (Venclexta) in combination with azacitidine failed to improve overall survival in newly diagnosed patients with higher-risk myelodysplastic syndromes, AbbVie ...

"Aptose is incredibly grateful for Hanmi's continued support tuspetinib,” said William G. Rice, Ph.D., Chairman, President ...

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded ...

Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia ...

Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...